Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
Source:
Nasdaq GlobeNewswire
/
16 Apr 2024 20:01:49 America/New_York
N/A
Share on,